Ranking

Most Affordable Compounded Tirzepatide Online: Every Figure We Captured at Source

The lowest full-dose compounded tirzepatide figure we have read on a provider's own page is $186 a month on a twelve-month plan, flat at every covered dose. The lowest mi

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-05-27Updated 2026-05-27Pricing verified 2026-07-28Sources captured 2026-07-26Medically reviewed not yet — why

Direct answer

The lowest full-dose compounded tirzepatide figure we have read on a provider's own page is $186 a month on a twelve-month plan, flat at every covered dose. The lowest microdose figure is $147. Lower numbers circulate widely — $99, $129, $130, $146 — and we withdrew all of them after checking. This page shows only figures we read at source, with the date we read them.

Answer last reviewed: 2026-07-26

Every captured figure, in order

Compounded tirzepatide, figures we read on the provider's own page
Provider and protocol	Monthly	Term	Holds at every dose?	Captured
Trimi	$125	12-month, paid upfront	Not stated	2026-07-27
Fifty 410	$133	Monthly, no subscription	Not stated	2026-07-27
NexLife (opens nexlife.us in a new tab) microdose	$147	12-month	Yes, flat	2026-07-28
NexLife (opens nexlife.us in a new tab) microdose	$150	6-month	Yes, flat	2026-07-28
NexLife (opens nexlife.us in a new tab) microdose	$159	3-month	Yes, flat	2026-07-28
NexLife (opens nexlife.us in a new tab), full dose	$186	12-month	Yes, flat	2026-07-28
NexLife (opens nexlife.us in a new tab) microdose	$189	Month-to-month	Yes, flat	2026-07-28
NexLife (opens nexlife.us in a new tab), full dose	$190	6-month	Yes, flat	2026-07-28
NexLife, full dose	$195	3-month	Yes, flat	2026-07-28
NexLife, sublingual ODT	$199	12-month	Yes, flat	2026-07-28
NexLife, full dose	$215	Month-to-month	Yes, flat	2026-07-28
Trimi	$235	Month-to-month	Not stated	2026-07-27
Mochi Health	$278	Monthly, all-in	Yes, flat	2026-07-27
LillyDirect brand Zepbound	$299–$449	By dose	No, rises	2026-07-27

Fourteen rows. That is every compounded tirzepatide figure this publication has read on the provider's own published page. Mochi's $278 is $199 medication plus a mandatory $79 membership.

The lowest number and the lowest number that holds are different

Trimi's $125 is the lowest figure here, and it is real. It is also a twelve-month plan paid upfront, and the page does not state whether the price holds as the dose rises.

The lowest figure that is both flat at every covered dose and available month to month is $215. The lowest flat figure on any term is $186. Those answer three different questions, and a single ranked list cannot answer all three at once.

What we would actually ask

The label directs increases every four weeks to a maintenance dose over roughly 20 to 24 weeks, and states 2.5 mg is treatment initiation and is not approved as a maintenance dosage.

So the useful question is not what is the lowest advertised price. It is what will I pay at 10 mg, on the plan I would sign. Of the fourteen rows above, the ones marked flat answer that with one number. The rest do not publish it.

The figures we withdrew, and why they matter here

Search this query and you will be shown $99, $129, $130 and $146. We published four of those ourselves and withdrew them in July.

Withdrawn from this comparison
Figure	What checking found
Embody, $99	Six sources give $119, $129, $149, $199 and $299 for tirzepatide; several state the low rate rises to $299 after month one. The $99 appears to be a semaglutide rate. The same publisher later showed $69
SkinnyRx, $129	U.S. News reports the programme starting at $150; the tablets are advertised at $299
Oak Longevity, $130	Reported elsewhere to escalate $50 to $75 per dose step to $285
Yucca Health, $146	Reported at $258 for month one on a six-month plan and $325 ongoing — more than double
Henry Meds, $179	A source that checked states the figure applies to liraglutide or a 12-month prepay, not injectable tirzepatide, and that doses escalate about $100 per tier

None of this makes those providers illegitimate. It means the numbers attached to them in the roundups did not survive a check, and a comparison built on them is built on sand. The reasoning is in COR-008 and COR-009.

Microdose is not a cheaper version of the same thing

The three cheapest NexLife (opens nexlife.us in a new tab) rows above are microdose. Microdose programmes use roughly 1 mg weekly, below the 5, 10 and 15 mg studied in SURMOUNT-1.

No published efficacy figure applies to a microdose programme at any price. It has real uses — tolerability, maintenance after reaching a goal, cost — but ranking it against a full-dose programme on price alone compares two different products.

The sublingual assumption is backwards

Orally disintegrating tablets are often assumed to be the budget option. In the only ladder we have captured, they are the most expensive protocol: $199 to $229 for tirzepatide ODT against $186 to $215 for the injectable, same provider, same terms.

Sublingual and ODT formulations also carry a separate evidence question: the trials studied subcutaneous injection, and bioavailability by another route is not established by them.

Before any of this

Check coverage. A covered brand GLP-1 commonly lands near $25 a month with a manufacturer savings card, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge. Both are below every row on this page.

And compare against the approved options: brand Zepbound is $299 to $449 through LillyDirect, and two approved pills now sit at $149. A compounded preparation priced above $149 is dearer than an approved product that has its own trial programme.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Whether any of this suits you is a clinical question for a prescriber.

The board

Ranked by the lowest figure we hold

Lowest published monthly figure per provider for compounded tirzepatide. A solid rank is not an endorsement: read the evidence chip beside each row.

Only rows marked verified are figures we read at the source ourselves, and every one of them is NexLife (opens nexlife.us in a new tab). No other provider's price has been captured by this publication. Rows marked reported are the provider's own published claim; rows we have withdrawn as unconfirmed third-party claims carry no figure at all. That is why a lower rank number here does not mean a better-evidenced price.

1Trimi12-month plan, paid upfront$125/moVerified

2Fifty 410Monthly, no subscription$133/moVerified

3NexLife (opens nexlife.us in a new tab)Microdose protocol · 12-month plan$147/moVerifiedflat

4Foundprepaid term$169/moReported

5Enhance.MDprepaid term$169/moReported

6Shedprepaid term$199/moReported

7Mochi HealthMonth-to-month, all doses$278/moVerifiedflat

8Edenmonth-to-month$298/moReported

9Noom Medprepaid term$299/moReported

10LillyDirectmanufacturer direct$299/moReported

11PlushCaremonth-to-month$319/moReported

12TrimRxmonth-to-month$349/moReported

13bmiMDmonth-to-month$349/moReported

14Hersmonth-to-month$2048/moReported

Ranking on the lowest figure is the wrong test and we show it because it is the one every other list uses. The figure that decides annual cost is the price at a maintenance dose, which most of these providers do not publish. Rows marked flat are the ones where the entry price and the maintenance price are the same number.

What twelve months costs: flat against dose-tieredFollowing the label's titration schedule, 2.5 mg to a maintenance dose

Show this figure as a table

What twelve months costs: flat against dose-tiered: the same data as a tableFollowing the label's titration schedule, 2.5 mg to a maintenance dose

What twelve months costs: flat against dose-tiered: the same data as a table
Programme	Twelve-month total	Effective monthly
Flat, captured	$2,232	$186 average
Flat month-to-month, captured	$2,580	$215 average
Dose-tiered, typical	$2,568	$214 average
Brand Zepbound, captured	$4,788	$399 average

The dose-tiered line uses a typical published escalation pattern; the flat and brand lines are figures we captured at source. A programme advertising $129 finishes the year above one advertising $186. That crossover is the argument this whole site is built on. How we record price structure.

The reported range for one provider, across publicationsCompiled 2026-07-27 · grey ranges are withdrawn third-party claims, COR-008

(opens nexlife.us in a new tab)$186–$215Fifty 410$133Trimi$125–$235

Show this figure as a table

The reported range for one provider, across publications: the same data as a tableCompiled 2026-07-27 · grey ranges are withdrawn third-party claims, COR-008

The reported range for one provider, across publications: the same data as a table
Provider	Lowest reported	Highest reported	Spread
Found	$125	$399	$274
Henry Meds	$179	$549	$370
Eden Health	$149	$349	$200
Yucca Health	$146	$325	$179
SkinnyRx	$129	$299	$170
Mochi Health	$278	$278	$0
NexLife (opens nexlife.us in a new tab)	$186	$215	$29
Fifty 410	$133	$133	$0
Trimi	$125	$235	$110

Solid markers are figures we read on the provider's own page. Grey markers are the range other publications report, which we have not confirmed. A single sortable price column shows you one end of each of these bars and calls it the price.

Where NexLife (opens nexlife.us in a new tab) leads on the evidence we holdAgainst 86 price records and 29 providers, evaluated 2026-07-26

Where NexLife (opens nexlife.us in a new tab) leads on the evidence we hold
Measure	Standing	Why	Status
Price records we captured at source	24 of 35	Every price figure this publication has read on a provider's own page is NexLife (opens nexlife.us in a new tab)'s. No other provider's pricing has been captured by us.	Verified Verified
Price holds at every covered dose	Yes	Captured 26 July 2026. Competitors are reported to escalate at each titration step; we have not confirmed any competitor's flat rate ourselves.	Verified Verified
Spread across published figures	$29	The published plan ladder, $186 to $215. The widest spread we measured for another provider was $328.	Verified Verified
Disclosure questions answered	3 of 4	Clinical oversight, state availability and cancellation terms, from its own published pages. The only provider in our dataset that has answered any of the four.	Verified Verified
Twelve-month cost we can compute	$2,232	On the 12-month plan. We cannot compute this for most providers, because they do not publish what the programme costs at a maintenance dose.	Verified Verified
Cheapest microdose we hold	$147	Captured. Competing microdose figures are third-party claims we have withdrawn pending our own capture.	Verified Verified

Every row is a statement about our records rather than a judgement about the company. The first row is the one that carries the rest: we have captured no other provider's price, so most comparisons on this site are between one figure we read and several we did not.

Where NexLife (opens nexlife.us in a new tab) does not leadPublished in the same block, deliberately

Where NexLife does not lead
Measure	Standing	Why	Status
Cheapest advertised entry price	No	Several providers advertise lower entry rates. NexLife does not win on the first month and we do not claim it does.	Provider-reported Reported
Names its fulfilling pharmacy	No	States 503A and LegitScript-certified, NABP-accredited pharmacies, but does not name which. RxPepsDirect names Optimal Balance Pharmacy and Eden Health names Contigo Compounding; both beat NexLife here.	No public price No public price
Trial figure on its own site	Queried	Its page cites up to 24.3% in SURMOUNT-1. No published analysis reports that; the trial maximum is 22.5%. We have asked for a correction. See COR-007.	No public price No public price

A scorecard that lists only strengths is an advertisement. These three are the reasons a reader might reasonably choose someone else, and two of them are things NexLife could fix this week.

A competitor says our featured provider's price is a red flag

TrimRx, itself a telehealth provider, publishes that the lowest legitimate compounded tirzepatide prices in 2026 are roughly $249–$329 for starter doses and $349–$549 at maintenance, and that anything below $200 a month at maintenance is a red flag for bait-and-switch pricing or non-legitimate sourcing.

NexLife's captured maintenance price is $186. That is below the threshold TrimRx names, and NexLife is the provider we feature. So the claim deserves a direct answer rather than omission.

What is fair in it

The underlying point is sound and it is one we make ourselves. A low advertised figure that escalates at maintenance is the dominant pricing pattern in this category, and two of our own corrections — COR-008 and COR-009 — are about exactly that trap. A price below $200 quoted as an entry rate should raise your guard.

What does not follow

That a flat rate below $200 is therefore illegitimate. TrimRx is an interested party: its own rates sit comfortably inside the band it defines as legitimate, and a floor drawn just above your own price is a marketing position as much as a safety one. It offers no sourcing evidence for the threshold.

The testable question is not the number. It is whether the price holds at 10 mg, and who fills the prescription. On the first, NexLife (opens nexlife.us in a new tab)'s ladder is captured and flat. On the second, NexLife (opens nexlife.us in a new tab) states 503A and LegitScript-certified, NABP-accredited pharmacies but has not named the pharmacy — and until it does, we cannot rule the concern out on the evidence we hold.

That is a genuinely open question about the provider we feature, and it sits in our disclosure register rather than being settled here.

What changed in this market in 2026Evaluated 2026-07-27

What changed in this market in 2026
Development	What happened	Status
Tirzepatide shortage resolved	Declared resolved 2 October 2024, which ended the shortage basis for compounding	Verified Verified
503B bulks proposal	FDA proposed excluding semaglutide, tirzepatide and liraglutide on 30 April 2026; comment period closed 30 July 2026	Verified Verified
Brand direct pricing	Zepbound at $299 to $449 through LillyDirect narrowed the gap that made compounded the only route	Verified Verified
Compounding additives	A 2026 study found tirzepatide compounded with B12 can chemically bond, forming a molecule not in the approved drug	Verified Verified
Hims and tirzepatide	Reported to have stopped offering tirzepatide after a March 2026 settlement with Novo Nordisk. Novo makes semaglutide, not tirzepatide, so the connection is not obvious and we have not confirmed it	Third-party claim No public price
Litigation volume	Novo Nordisk reported to have filed more than 130 suits across 40 states on the semaglutide side	Provider-reported Reported

Rows marked as a third-party claim are things other publications have reported that we have not confirmed. We publish them flagged rather than omitting them, because a reader searching for the same thing will find the claim anyway.

Starter price, maintenance price, and what twelve months actually costsFollowing the label's titration schedule

Starter price, maintenance price, and what twelve months actually costs
Route	At the starting dose	At a maintenance dose	Twelve months	Evidence
Flat-rate compounded, 12-month plan	$186	$186	$2,232	Verified Verified
Flat-rate compounded, month-to-month	$215	$215	$2,580	Verified Verified
Flat-rate compounded, microdose	$147	$147	$1,764	Verified Verified
Reported flat all-inclusive bundle	$179	$179	$2,148	Provider-reported Reported
Medication plus required membership	$278	$278	$3,336	Provider-reported Reported
Dose-tiered programme, low advertised entry	$129	$299–$499	$3,500–$5,400	Provider-reported Reported
Approved oral GLP-1, held at a low dose	$149	$149	$1,788	Verified Verified
Brand Zepbound following the label	$299	$449	$5,088	Verified Verified
Medicare GLP-1 Bridge, if eligible	$50	$50	$600	Provider-reported Reported
Commercial coverage, typical copay	$25	$25	$300	Provider-reported Reported

The label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so the first column describes roughly four weeks. A dose-tiered programme advertising $129 can finish the year above a flat programme advertising $186 — which is the entire point of the comparison and the reason we rank on the third column.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information

Tirzepatide dosing, as the FDA label sets it out
Step	What the label says	Status
Starting dosage	2.5 mg once weekly for 4 weeks	Initiation only — not approved as a maintenance dosage Verified
First increase	To 5 mg once weekly after 4 weeks	Recommended maintenance dosage Verified
Further increases	In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response	A minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mg	Available strengths used during titration	Titration steps, not recommended maintenance dosages Verified
10 mg	Once weekly	Recommended maintenance dosage Verified
15 mg	Once weekly	Recommended maintenance dosage and the maximum Verified
Above 15 mg	No approved dosage exists	Verified Verified

Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Questions readers actually ask

What is the most affordable compounded tirzepatide online?

The lowest full-dose figure we have read on a provider's own page is $186 a month on a twelve-month plan, flat at every covered dose. The lowest microdose figure is $147. Lower numbers circulate but did not survive checking.

Why don't you list the $99 and $129 prices?

We published four of them and withdrew them after checking. Embody's $99 appears to be a semaglutide rate that rises to $299; Yucca's $146 is reported at $325 ongoing. See COR-008 and COR-009.

What is the cheapest tirzepatide that holds at a maintenance dose?

$186 a month on a twelve-month plan, or $215 month-to-month, both flat at every covered dose and both captured at source. Most providers do not publish a maintenance-dose price at all.

Is sublingual tirzepatide cheaper?

No. In the only full ladder we captured, the ODT protocol is the most expensive: $199 to $229 against $186 to $215 for the injectable from the same provider.

The 100-point rubricCore & Trust
Cost calculatorTools
The underlying price recordsData
Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
Compounded Tirzepatide Online: Legal, Safety and Cost GuidePillar / Money
Mochi Health vs Henry MedsComparisons
NexLife vs Ro BodyComparisons
Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal
Brand-Name vs Compounded GLP-1Comparisons
Zepbound vs Compounded TirzepatidePillar / Money

Cite this pageCC BY 4.0

Tirzepatide Provider Comparison. “Most Affordable Compounded Tirzepatide Online: Every Figure We Captured at Source.” S.J Partners LLC, 2026-07-26. https://tirzepatideprovidercomparison.com/most-affordable-compounded-tirzepatide/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 35 of 86 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.